A condition characterized by recurrent episodes of daytime somnolence and lapses in consciousness (microsomnias) that may be associated with automatic behaviors and AMNESIA. CATAPLEXY; SLEEP PARALYSIS, and hypnagogic HALLUCINATIONS frequently accompany narcolepsy. The pathophysiology of this disorder includes sleep-onset rapid eye movement (REM) sleep, which normally follows stage III or IV sleep. (From Neurology 1998 Feb;50(2 Suppl 1):S2-S7)
A condition characterized by transient weakness or paralysis of somatic musculature triggered by an emotional stimulus or physical exertion. Cataplexy is frequently associated with NARCOLEPSY. During a cataplectic attack, there is a marked reduction in muscle tone similar to the normal physiologic hypotonia that accompanies rapid eye movement sleep (SLEEP, REM). (From Adams et al., Principles of Neurology, 6th ed, p396)
Subjectively experienced sensations in the absence of an appropriate stimulus, but which are regarded by the individual as real. They may be of organic origin or associated with MENTAL DISORDERS.
A sleep disorder of central nervous system origin characterized by prolonged nocturnal sleep and periods of daytime drowsiness. Affected individuals experience difficulty with awakening in the morning and may have associated sleep drunkenness, automatic behaviors, and memory disturbances. This condition differs from narcolepsy in that daytime sleep periods are longer, there is no association with CATAPLEXY, and the multiple sleep latency onset test does not record sleep-onset rapid eye movement sleep. (From Chokroverty, Sleep Disorders Medicine, 1994, pp319-20; Psychiatry Clin Neurosci 1998 Apr:52(2):125-129)
Peptides released by NEURONS as intercellular messengers. Many neuropeptides are also hormones released by non-neuronal cells.
A common condition characterized by transient partial or total paralysis of skeletal muscles and areflexia that occurs upon awakening from sleep or less often while falling asleep. Stimuli such as touch or sound may terminate the episode, which usually has a duration of seconds to minutes. This condition may occur in normal subjects or be associated with NARCOLEPSY; CATAPLEXY; and hypnagogic HALLUCINATIONS. The pathophysiology of this condition is closely related to the normal hypotonia that occur during REM sleep. (From Adv Neurol 1995;67:245-271)
Transmembrane proteins that form the beta subunits of the HLA-DQ antigens.
The temporal sequence of events that have occurred.
A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)
A general term most often used to describe severe or complete loss of muscle strength due to motor system disease from the level of the cerebral cortex to the muscle fiber. This term may also occasionally refer to a loss of sensory function. (From Adams et al., Principles of Neurology, 6th ed, p45)
A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
The immersion or washing of the body or any of its parts in water or other medium for cleansing or medical treatment. It includes bathing for personal hygiene as well as for medical purposes with the addition of therapeutic agents, such as alkalines, antiseptics, oil, etc.
A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
An involuntary expression of merriment and pleasure; it includes the patterned motor responses as well as the inarticulate vocalization.
A surgical specialty concerned with the treatment of diseases and disorders of the brain, spinal cord, and peripheral and sympathetic nervous system.
A medical specialty concerned with the study of the structures, functions, and diseases of the nervous system.
Autoantibodies directed against various nuclear antigens including DNA, RNA, histones, acidic nuclear proteins, or complexes of these molecular elements. Antinuclear antibodies are found in systemic autoimmune diseases including systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, and mixed connective tissue disease.
Relatively complete absence of oxygen in one or more tissues.
Cells specialized to detect chemical substances and relay that information centrally in the nervous system. Chemoreceptor cells may monitor external stimuli, as in TASTE and OLFACTION, or internal stimuli, such as the concentrations of OXYGEN and CARBON DIOXIDE in the blood.
The total volume of gas inspired or expired per unit of time, usually measured in liters per minute.
A clinical manifestation of abnormal increase in the amount of carbon dioxide in arterial blood.
Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes.
The rostral part of the frontal lobe, bounded by the inferior precentral fissure in humans, which receives projection fibers from the MEDIODORSAL NUCLEUS OF THE THALAMUS. The prefrontal cortex receives afferent fibers from numerous structures of the DIENCEPHALON; MESENCEPHALON; and LIMBIC SYSTEM as well as cortical afferents of visual, auditory, and somatic origin.
A family of small, gram-negative organisms, often parasitic in humans and other animals, causing diseases that may be transmitted by invertebrate vectors.
A disorder caused by hemizygous microdeletion of about 28 genes on chromosome 7q11.23, including the ELASTIN gene. Clinical manifestations include SUPRAVALVULAR AORTIC STENOSIS; MENTAL RETARDATION; elfin facies; impaired visuospatial constructive abilities; and transient HYPERCALCEMIA in infancy. The condition affects both sexes, with onset at birth or in early infancy.
Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.
Imaging techniques used to colocalize sites of brain functions or physiological activity with brain structures.
Disorders characterized by hypersomnolence during normal waking hours that may impair cognitive functioning. Subtypes include primary hypersomnia disorders (e.g., IDIOPATHIC HYPERSOMNOLENCE; NARCOLEPSY; and KLEINE-LEVIN SYNDROME) and secondary hypersomnia disorders where excessive somnolence can be attributed to a known cause (e.g., drug affect, MENTAL DISORDERS, and SLEEP APNEA SYNDROME). (From J Neurol Sci 1998 Jan 8;153(2):192-202; Thorpy, Principles and Practice of Sleep Medicine, 2nd ed, p320)
A central nervous system stimulant used in fatigue and depressive states and to treat hyperkinetic disorders in children.
That branch of learning which brings together theories and studies on communication and control in living organisms and machines.

Unilateral cataplexy associated with systemic lupus erythematosus. (1/120)

A patient with systemic lupus erythematosus (SLE) developed attacks of unilateral cataplexy precipitated by laughter. Unilateral cataplexy has not been described previously in detail and its association with SLE is unique. The clinical details, investigations, and diagnostic criteria are discussed and a causal relationship between cataplexy and SLE is suggested.  (+info)

Sulpiride, a D2/D3 blocker, reduces cataplexy but not REM sleep in canine narcolepsy. (2/120)

Cataplexy, an abnormal manifestation of REM sleep atonia, is currently treated with antidepressants. These medications also reduce physiological REM sleep and induce nocturnal sleep disturbances. Because a recent work on canine narcolepsy suggests that the mechanisms for triggering cataplexy are different from those for REM sleep, we hypothesized that compounds which act specifically on cataplexy, but not on REM sleep, could be developed. Canine studies also suggest that the dopamine D2/D3 receptor mechanism is specifically involved in the regulation of cataplexy, but little evidence suggests that this mechanism is important for REM sleep regulation. We therefore assessed the effects of sulpiride, a commonly used D2/D3 antagonist, on cataplexy and sleep in narcoleptic canines to explore the possible clinical application of D2/D3 antagonists for the treatment of human narcolepsy. Both acute and chronic oral administration of sulpiride (300 mg/dog, 600 mg/dog) significantly reduced cataplexy without noticeable side effects. Interestingly, the anticataplectic dose of sulpiride did not significantly reduce the amount of REM sleep. Sulpiride (and other D2/D3 antagonists) may therefore be an attractive new therapeutic indication in human narcolepsy.  (+info)

Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. (3/120)

Human narcolepsy-cataplexy, a sleep disorder associated with a centrally mediated hypocretin (orexin) deficiency, is tightly associated with HLA-DQB1*0602. Few studies have investigated the influence that additional HLA class II alleles have on susceptibility to this disease. In this work, 1,087 control subjects and 420 narcoleptic subjects with cataplexy, from three ethnic groups, were HLA typed, and the effects of HLA-DRB1, -DQA1, and -DQB1 were analyzed. As reported elsewhere, almost all narcoleptic subjects were positive for both HLA-DQA1*0102 and -DQB1*0602. A strong predisposing effect was observed in DQB1*0602 homozygotes, across all ethnic groups. Relative risks for narcolepsy were next calculated for heterozygous DQB1*0602/other HLA class II allelic combinations. Nine HLA class II alleles carried in trans with DQB1*0602 were found to influence disease predisposition. Significantly higher relative risks were observed for heterozygote combinations including DQB1*0301, DQA1*06, DRB1*04, DRB1*08, DRB1*11, and DRB1*12. Three alleles-DQB1*0601, DQB1*0501, and DQA1*01 (non-DQA1*0102)-were found to be protective. The genetic contribution of HLA-DQ to narcolepsy susceptibility was also estimated by use of lambda statistics. Results indicate that complex HLA-DR and -DQ interactions contribute to the genetic predisposition to human narcolepsy but that additional susceptibility loci are also most likely involved. Together with the recent hypocretin discoveries, these findings are consistent with an immunologically mediated destruction of hypocretin-containing cells in human narcolepsy-cataplexy.  (+info)

Health-related quality of life in narcolepsy. (4/120)

Narcolepsy is a chronic sleep disorder characterised by symptoms of excessive daytime sleepiness and cataplexy. The aim of this study was to describe the health-related quality of life of people with narcolepsy residing in the UK. The study comprised a postal survey of 500 members of the UK narcolepsy patient association, which included amongst other questions the UK Short Form 36 (SF-36), the Beck Depression Inventory (BDI), and the Ullanlinna Narcolepsy Scale (UNS). A total of 305 questionnaires were included in the final analysis. The results showed that the subjects had significantly lower median scores on all eight domains of the SF-36 than normative data, and scored particularly poorly for the domains of role physical, energy/vitality, and social functioning. The BDI indicated that 56.9% of subjects had some degree of depression. In addition, many individuals described limitations on their education, home, work and social life caused by their symptoms. There was little difference between the groups receiving different types of medication. This study is the largest of its type in the UK, although the limitations of using a sample from a patient association have been recognised. The results are consistent with studies of narcolepsy in other countries in demonstrating the extensive impact of this disorder on health-related quality of life.  (+info)

Increased and decreased muscle tone with orexin (hypocretin) microinjections in the locus coeruleus and pontine inhibitory area. (5/120)

Orexin-A (OX-A) and orexin-B (OX-B) (hypocretin 1 and hypocretin 2) are synthesized in neurons of the perifornical, dorsomedial, lateral, and posterior hypothalamus. The locus coeruleus (LC) receives the densest extrahypothalamic projections of the orexin (OX) system. Recent evidence suggests that descending projections of the LC have a facilitatory role in the regulation of muscle tone. The pontine inhibitory area (PIA), located ventral to LC, receives a moderate OX projection and participates in the suppression of muscle tone in rapid-eye-movement sleep. We have examined the role of OX-A and -B in muscle-tone control using microinjections (0.1 microM to 1 mM, 0.2 microl) into the LC and PIA in decerebrate rats. OX-A and -B microinjections into the LC produced ipsi- or bilateral hindlimb muscle-tone facilitation. The activity of LC units was correlated with the extent of hindlimb muscle-tone facilitation after OX microinjections (100 microM, 1 microl) into fourth ventricle. Microinjections of OX-A and -B into the PIA produced muscle-tone inhibition. We did not observe any significant difference in the effect of OX-A and -B on muscle tone at either site. Our data suggest that OX release activates LC units and increases noradrenergic tonus in the CNS. Moreover, OX-A and -B may also regulate the activity of pontine cholinoceptive and cholinergic neurons participating in muscle-tone suppression. Loss of OX function may therefore disturb both facilitatory and inhibitory motor processes.  (+info)

MAO-A and COMT polymorphisms and gene effects in narcolepsy. (6/120)

Narcolepsy presents one of the tightest associations with a specific HLA antigen (DQB1*0602) but there is strong evidence that non-HLA genes also confer susceptibility. Recent observations have implicated the hypocretin/orexin system in narcolepsy in both humans and animals. In addition, the implication of monoaminergic systems in the pathophysiology of narcolepsy is well established and a significant association between the monoamine oxydase-A (MAO-A) gene and human narcolepsy has recently provided a possible genetic link. We investigated polymorphisms of MAO-A and catechol-O-methyltransferase (COMT) in 97 Caucasians with well-defined narcolepsy-cataplexy and sought for genotypic effects on disease symptoms. No evidence of association between genotype or allele frequencies of both MAO-A or COMT gene and narcolepsy was found. However, a sexual dimorphism and a strong effect of COMT genotype on disease severity were found. Women narcoleptics with high COMT activity fell asleep twice as fast as those with low COMT activity during the multiple sleep latency test (MSLT) while the opposite was true for men. COMT genotype also strongly affected the presence of sleep paralysis and the number of REM sleep onsets during the MSLT. In agreement with well-documented pharmacological results in canine narcolepsy, this study reports the first genetic evidence for the critical involvement of the dopaminergic and/or noradrenergic systems in human narcolepsy.  (+info)

Childhood onset of narcolepsy-cataplexy syndrome in Turkey: clinical and genetic study. (7/120)

Narcolepsy is a disabling sleep disorder characterized by excessive daytime sleepiness and abnormal manifestations of rapid eye movement (REM) sleep including cataplexy, sleep paralysis and hypnagogic hallucinations. It is known to be complex disorder in which both genetic predisposition and environmental factors play a role. In humans, susceptibility to narcolepsy is tightly associated with a specific HLA allele, DQB1*0602. In this report, we took advantage of the ongoing genetic study in Turkish narcoleptic patients to document clinical and genetic data of eight patients whose onset of symptoms were in the childhood period.  (+info)

Hypocretin (orexin) deficiency in narcolepsy and primary hypersomnia. (8/120)

The discovery that hypocretins are involved in narcolepsy, a disorder associated with excessive daytime sleepiness, cataplexy, and unusually rapid transitions to rapid eye movement sleep, opens a new field of investigation in the area of disorders of sleep and activation. Hypocretin-1 (hcrt-1) and hypocretin-2 (hcrt-2) (also called orexin-A and orexin-B) are newly discovered neuropeptides processed from a common precursor. Hypocretin containing cells are located exclusively in the lateral hypothalamus, with widespread projections within the central nervous system. The role of the hypocretin system in other disorders causing excessive daytime sleepiness is more uncertain. This study reports the findings of a prospective study measuring cerebrospinal fluid concentrations of hypocretin-1 and hypocretin-2 in HLA DQB1*0602 positive narcolepsy with cataplexy, monosymptomatic narcolepsy, and primary hypersomnia. The results confirmed the previous observations, that hcrt-1 is deficient in narcolepsy and for the first time report very low levels of hcrt-1 in primary hypersomnia. It is also reported for the first time that there is a generalised defect in hcrt-2 transmission in all three of these clinical entities compared with controls.  (+info)

Orexin (hypocretin)-containing neurons of the hypothalamus project to brainstem sites that are involved in the neural control of REM sleep, including the locus coeruleus, the dorsal raphe nucleus, the cholinergic zone of the mesopontine tegmentum, and the pontine reticular formation (PRF). Orexin knockout mice exhibit narcolepsy/cataplexy, and a mutant and defective gene for the orexin type II receptor is present in dogs with an inherited form of narcolepsy/cataplexy. However, the physiological systems mediating these effects have not been described. We reasoned that, since the effector neurons for the majority of REM sleep signs, including muscle atonia, were located in the PRF, this region was likely implicated in the production of these orexin-related abnormalities. To test this possibility, we used microdialysis perfusion of orexin type II receptor antisense in the PRF of rats. Ten to 24 hours after antisense perfusion, REM sleep increased two- to three-fold during both the light period ...
A patient with systemic lupus erythematosus (SLE) developed attacks of unilateral cataplexy precipitated by laughter. Unilateral cataplexy has not been described previously in detail and its association with SLE is unique. The clinical details, investigations, and diagnostic criteria are discussed and a causal relationship between cataplexy and SLE is suggested.. ...
Cataplexy is estimated to be present in ~70% of Narcolepsy cases, but I had heard that the severe form affects less than 10-15%. It is said that Narcolepsy with Cataplexy, affects about one in every 3,000 Americans. More cases without Cataplexy are likely to exist.. In the research for this post, I came across Predictors of Hypocretin (Orexin) Deficiency in Narcolepsy with Cataplexy, where the thresholds are revealed to be from statistical analysis, using R. Where the optimal cutoff for CSF Hypocretin-1, the ROC curve analysis defines a gold standard of approximately 200 pg/mL as the cutoff for the diagnosis of Narcolepsy without Cataplexy vs those with, and is convenient with previously defined cut offs of low (,=110), intermediate (,=200), or normal (>200), where Narcolepsy with Cataplexy are those with 110 pg/ml or less. Intermediate….do we really exist? From what I recall reading (while I was required to lay as still as possible on back follow the spinal tap), those values were again ...
Approximately twenty-five percent of sleep is REM in the young adult [13] but interestingly, this varies with age [14]. We know that infants have much more REM compared to adults, as human infants typically enter REM sleep directly after the initial onset of sleep and spend approximately 50% of their total sleep time in REM [15]. And we also know that as we age, cartilaginous structures desiccate [16]. During development, infants have much more cartilaginous tissue compared to adults while they undergo the metabolic demanding task of endochondral ossification. Chondrocytes constitute the predominant cell of cartilage which is an interface tissue that is avascular, aneural and alymphatic [17]. These cells lay in an environment that is influenced by mechanical forces [18] whereby cellular perception of mechanical stress within cartilaginous tissues is an important modulator of chondrocyte function [19]. Recent understandings of growth plate proliferation have revealed that distraction is ...
Oishi, Y.; Williams, R.H.; Agostinelli, L.; Arrigoni, E.; Fuller, P.M.; Mochizuki, T.; Saper, C.B.; Scammell, T.E., 2013: Role of the medial prefrontal cortex in cataplexy
Trust me, I know it seems weird. I fainted in the shower on Sunday and felt fine Monday but when I called to make an appointment just to get it checked out they asked that I go to the ER, so I did. I was reluctant because it didnt seem like a huge deal -- it was probably just hypotension from the heat -- but everyone else waiting at the ER was also there for something that wasnt obviously immediately killing them. You dont mess around with neurological things, fainting, etc, for good reason. If it was a stroke, which is possible, you need to go get it checked out ASAP. If it wasnt a stroke, you still need to know what it was. No ones going to get angry at you for showing up if it doesnt end up being serious ...
I am 34 and was dxd with Narcolepsy/Cataplexy last year after searching for answers for a very long time. I have white matter and grey matter spots/lesions that are unenhanced with contrast (demyelin...
Association of cataplexy with EDS with another disorder of the brain was first reported in the early 1900. These associations includes tumors, localized most
Narcolepsy is an orphan sleep disorder (0.026% of the general population) characterized by a clinical history of EDS and abnormal manifestations of dissociated REM sleep, such as cataplexy (that is, sudden loss of muscle tone triggered by strong emotions), hypnagogic hallucinations, and sleep paralysis [59]. Narcolepsy typically starts during adolescence, a critical period of normal development and interpersonal relationship building [60]. Cataplexy is the best clinical diagnostic marker for the disease, occurring in 70% to 80% of patients. Two separate entities are individualized: narcolepsy with and without cataplexy [11]. Narcolepsy diagnosis requires nocturnal PSG recording followed by the MSLT, the latter showing a mean sleep latency ,8 minutes and two or more sleep onset REM periods (SOREMPs).. For 120 years after it was identified, narcolepsy was attributed to psychiatric etiologies [61]. In the 2000s, however, it was determined that when cataplexy is present, narcolepsy is almost always ...
BACKGROUND: Rapid eye movement (REM) sleep behaviour disorder (RBD) is a common sleep disorder that can be associated with a number of neurodegenerative conditions as well as with narcolepsy. Current diagnostic criteria require overnight polysomnography, and there are no other biomarkers available. The control of REM sleep is complex with a putative on/off switch within the brainstem activated, amongst other things, by hypocretinergic pathways from the lateral hypothalamus. METHODS: Cerebrospinal fluid hypocretin levels were measured in five patients with idiopathic RBD. RESULTS: Hypocretin levels were between 254 and 450 pg/ml and therefore within the normal range of |100 pg/ml. CONCLUSION: Hypocretin levels in patients with idiopathic RBD are normal.
There are two kinds of narcolepsy: one with cataplexy, and the other without. Cataplexy is a sudden loss of muscle control when the person can fall or slur their words and is often caused by an emotion such as laughter or some kind of excitement. During cataplexy, the person is awake.. Narcolepsy without cataplexy is often less severe than with cataplexy, and its a sleep disorder that can cause the sudden onset of sleep, sleep paralysis, hallucinations, and excessive sleepiness. It affects around 1 in 2,000 people. People with narcolepsy can be very tired during the day, and have vivid hallucinations and sleep paralysis while falling asleep and waking up. They also have disturbed sleep at night because the brain doesnt go through the normal flow through the different phases of sleep-people with narcolepsy can go directly from waking to REM (rapid eye movement) sleep, bypassing light sleep and deep sleep. ...
Narcolepsy and Cataplexy Symptoms and Treatments in Dogs - Narcolepsy and cataplexy are uncommon disorders of the sleep mechanism in which a dog is excessively sleepy all day (narcolepsy) or experiences sudden muscle paralysis and collapse (cataplecy). Between attacks the dog is completely normal.
To investigate the abnormality of cerebral perfusion in narcoleptics with cataplexy, cerebral perfusion was measured by brain single photon emission computed tomography(SPECT). The difference of cerebral perfusion between narcoleptics and normal controls was tested by statistical parametric mapping(SPM) analysis. Twenty-five narcoleptics with cataplexy and 25 normal controls performed 99mTc-ethylcysteinate dimer brain SPECT study. A night polysomnography and multiple sleep latency test (MSLT) in next day were performed in all patients. Brain SPECT was carried out in all patients and normal controls during waking state. The clinical symptoms and the results of MSLT were concordant to the International Classification of Sleep Disorders criteria for narcolepsy in all patients. The MSLT showed short mean sleep latency(1.69±1.0 min) and 2 - 5 sleep onset REM periods per each patient. The SPM analysis of brain SPECT in narcoleptics with cataplexy showed hypoperfusion in bilateral anterior ...
Sigma-Aldrich offers abstracts and full-text articles by [Akiko Ozaki, Yuichi Inoue, Kenichi Hayashida, Toru Nakajima, Makoto Honda, Akira Usui, Yoko Komada, Mina Kobayashi, Kiyohisa Takahashi].
Narcolepsy is a neurological order with symptoms like cataplexy (a debilitating condition in which a person collapses after strong emotions) and hallucinations. Treatment depends upon the severity of the symptoms of narcolepsy, but usually it is treated with drugs. The causes of narcolepsy are not clearly understood.
Posted on: 26th April 2016. On Wednesday 4th May 2016, the High Court will consider an application by the father of a child for judicial review of a decision by NHS England to refuse funding for a drug Sodium Oxybate (brand name Xyrem®) used to treat narcolepsy. The Court will be asked to intervene to require NHS England to fund the only treatment which has a real prospect of reducing the symptoms of this devastating illness.. The Claimant, X, is a 17 year old woman who has narcolepsy and cataplexy, a serious neurological condition causing disruption to night-time sleep, excessive daytime sleepiness, hypnogogic hallucinations and cataplexy.. Since 2012 the Claimant had been prescribed a range of medications to treat her condition including stimulants to help stay awake during the day, other drugs to assist with night-time sleep and further drugs for cataplexy. Unfortunately none of these were effective and in some cases the drugs caused negative side effects.. In May 2014 the Claimants NHS ...
Have you taken Xyrem within the past two years? Harvard Medical School and Brigham and Womens Hospital is currently conducting interviews to determine how FDA-mandated safety programs impact the prescribing and use of drugs like Xyrem.. Little is known about the impact of such programs on physicians, patients, and manufacturers, including whether they increase prescribing burdens, reduce patient access, enhance costs, or improve patients experiences with their illnesses. This study will seek to answer these questions. Participation will involve a 60-minute interview. Upon successful conclusion of the interview, study participants will receive a $50 Amazon gift card.. If you have received Xyrem within the past two years, you may be eligible. For more information, please contact the study principal investigator, Dr. Ameet Sarpatwari at [email protected].. Research Study is Enrolling to Evaluate Medications for Excessive Daytime Sleepiness ...
DISEASE: Narcolepsy 7 (NRCLP7) [MIM:614250]: Neurological disabling sleep disorder, characterized by excessive daytime sleepiness, sleep fragmentation, symptoms of abnormal rapid-eye- movement (REM) sleep, cataplexy, hypnagogic hallucinations, and sleep paralysis. Cataplexy is a sudden loss of muscle tone triggered by emotions, which is the most valuable clinical feature used to diagnose narcolepsy. Human narcolepsy is primarily a sporadically occurring disorder but familial clustering has been observed. Note=The disease is caused by mutations affecting the gene represented in this entry ...
I dont know if my RLS has changed, I know that I had previously, years ago, had a very bad case, which this previous regimine controlled for years. When I went off of all the drugs it was torture, but when I started the xyrem it was amazing, for the first time I really slept (narcolptics dont get any slow wave sleep, and have many abnormal rem onsets in sleep, etc). And then my whole life changed in the months after xyrem, whereas before I couldnt work or drive, now I could. It didnt just help my cataplexy it gor rid of the completly debilitating sleepiness of narcolepsy. Yes my RLS may have changed, but because I am now facing a situation where I could loose my livilhood, my dr said ok, lets just go back to the old regimne. The thing is it is helping the rls, and I am getting to seep, as I said before, but now Im tired today, and have been for the last 3 days, but I think Im not getting quality sleep, so tonight I will try backing off the xyrem...Im on the top dose, and see i thats ...
Title: Cell Transplantation: A Future Therapy for Narcolepsy?. VOLUME: 8 ISSUE: 4. Author(s):Oscar Arias-Carrion and Eric Murillo-Rodriguez. Affiliation:Experimental Neurology, Biomedical Research Center (BMFZ), Philipps University, Hans Meerwein Str., D-35043 Marburg, Germany.. Keywords:hypocretin/orexin neurons, narcolepsy, sleep, lateral hypothalamus, animal models, cell transplant. Abstract: Narcolepsy is a sleep disorder characterized by excessive daytime sleepiness, cataplexy, hypnagogic hallucinations, and sleep-onset rapid eye movement (REM) sleep periods. Narcolepsy is now identified to be a neurodegenerative disease, as there is a massive loss of neurons containing the neuropeptide, hypocretin/orexin. Orexin neurons are solely located in the hypothalamus, particularly in its perifornical, dorsomedial and lateral portions. Orexin fibers widely project throughout the brain and generally have excitatory effects on their postsynaptic cells. Patients with narcolepsy have a severe reduction ...
TY - JOUR. T1 - Narcolepsy. AU - Thorpy, Michael J.. PY - 2007/6/1. Y1 - 2007/6/1. N2 - Narcolepsy is a neurologic disorder that is incurable and therefore requires lifelong treatment. Excessive daytime sleepiness is the most common symptom and can be partially controlled by medications. The pathognomonic symptom of narcolepsy is cataplexy, emotionally induced muscle weakness, which can be the most disabling symptom for many patients. Also, hallucinations that typically occur at sleep onset or muscle paralysis that occurs upon awakening from sleep, called sleep paralysis, occur in many patients. Additional symptoms include fragmented nocturnal sleep and episodes of automatic behavior. Narcolepsy typically has its onset in the first 2 decades of life and may commonly be misdiagnosed. It produces reduced quality of life and, because of the sleepiness, can interfere with memory, concentration, and other cognitive abilities. The cataplexy may predispose the patient to injury because of the muscle ...
Narcolepsy is a chronic neurological disorder with unknown exact cause. Symptoms include periods of excessive daytime sleepiness that usually last from seconds to minutes and may occur at any time. About 70% of people also experience episodes of sudden loss of muscle strength, known as cataplexy. These spells can be brought on by strong emotions. Less commonly there may be inability to move or vivid hallucinations while falling asleep or waking up. People with narcolepsy tend to sleep about the same number of hours per day as people without, but the quality of sleep tends to be worse.. Diagnostic tests are carried out in the sleep clinic in order to measure each of these symptoms, thereby confirming presence of narcolepsy in patients. Diagnosis can be confirmed by polysomnography (Pic. 1) for assessing night-time sleep followed by a multiple sleep latency test to evaluate daytime sleep attacks lasting for a short period of time (Pic. 2). Mild cases of narcolepsy can be managed with regular naps, ...
Jerome Siegel, PhD, director of the Center for Sleep Research at the Jane and Terry Semel Institute for Neuroscience and Human Behavior at UCLA, and colleagues found that people with the disorder have nearly 65 percent more brain cells containing the chemical histamine. Their research suggests that this excess of histamine cells causes the loss of hypocretin cells in human narcoleptics.. Narcolepsy is a chronic disorder of the central nervous system that is believed to affect one-in-3,000 Americans. It is characterized by the brains inability to control sleep-wake cycles, causing sudden bouts of sleep. It often is accompanied by cataplexy, an abrupt loss of voluntary muscle tone that can cause a person to collapse.. Histamine is a body chemical that works as part of the immune system to kill invading cells. When the immune system goes awry, histamine can act on a persons eyes, nose, throat, lungs, skin or gastrointestinal tract, causing the symptoms of allergy that are familiar to many people. ...
Sleep Disorders. Narcolepsy. INtroduction to narcolepsy. what is narcolepsy? Causes of narcolepsy. How narcolepsy affects peoples lives?
According to the DSM-5, (Diagnostic and Statistical Manual of Mental Disorders, fifth edition), narcolepsy is a disorder in which the individual will experience recurrent periods of an irresistible need to sleep, or will fall asleep, or nap within the same day, regardless of whether or not the time and place are appropriate. These episodes must occur at least three times per week over the past three months, accompanied by at least one of the following symptoms:. 1. Episodes of cataplexy, or loss of muscle tonus, occurring several times a month, episodes lasting seconds to minutes of sudden full body loss of skeletal muscle tone without LOC (Loss Of Consciousness) that are precipitated by an episode of strong emotion. 2. In children or in individuals within six months of narcolepsy onset, involuntary grimacing or jaw-opening with tongue thrusting, or hypotonia, in the absence of clear emotional triggers.3. Objective measure of hypocretin deficiency in the cerebrospinal fluid (CSF) as defined by ...
We are clinician scientists board certified both in Sleep Medicine and Neurology with a combined 30 years of clinical experience that includes a particular focus on narcolepsy and related disorders collectively referred to as the central hypersomnias. We are well published in the area and regularly participate in the annual patient conferences of the Narcolepsy Network. We join with our patients in thanking you for your effort to reach out for input regarding the disease state(s) and especially the unmet needs of the patients who we treat. Having viewed the webcast of the recent September 24th public meeting on narcolepsy patient-focused drug development, we would like to add our voice to those of others.. Excessive daytime sleepiness remains common and the socioeconomic burden to the individual, family, and society is large. Unfortunately, while routine sleep laboratory testing for genuine narcolepsy with cataplexy is sensitive, it is becoming clear that it is highly nonspecific. The ...
What I meant about making yourself faint was...Can you manufacture a situation where you are certain to faint. Such as standing up fast, bending over etc. Have you ever fainted at the doctors office? I think You need to be hospitalized, hooked up to a monitor, blood pressure and oxygen saturation machines etc. Your physical parameters should change if you have witnessed syncope. (fainting). Narcolepsy as a possible diagnosis is interesting, as a symptom of it is called cataplexy. The most severe attacks result in a complete loss of tone in all voluntary muscles, leading to total physical collapse in which patients are unable to move, speak, or keep their eyes open. But even during the most severe episodes, people remain fully conscious, a characteristic that distinguishes cataplexy from seizure disorders. Although cataplexy can occur spontaneously, it is more often triggered by sudden, strong emotions such as fear, anger, stress, excitement, or humor. Laughter is reportedly the most frequent ...
Narcolepsy is being treated with stimulant drugs (amphetamines or methylphenidate) to control the excessive daytime sleepiness and sleep attacks, and imipramine to manage auxiliary symptoms, particularly cataplexy (1). The potentials for tolerance and dependence with the stimulants and cardiotoxicity from imipramine underscore the need for other therapies.. In 1978, we administered propranolol to a narcoleptic patient to treat premature ventricular contractions; a detailed report has been published elsewhere (2). When a relatively low dose of propranolol reduced the frequency of narcoleptic and cataplectic attacks, we gradually increased the dose. At a daily dose of about 300 mg, the attacks were ...
BACKGROUND: Several cross-sectional studies have suggested that subjects with narcolepsy have increased body mass index (BMI) and insulin resistance. These subjects exhibit a decrease in cerebrospinal fluid (CSF) orexin levels, which has been causally linked to the clinical manifestations of this disease. Orexins are peptides expressed in a brain region, the lateral hypothalamic area, which stimulate appetite and modulate sleep. Low CSF orexin levels provoke narcolepsy-like behavior, such as excessive daytime sleepiness and a sudden loss of muscle tone known as cataplexy.. OBJECTIVES: The primary objective of this study is to determine whether subjects with narcolepsy have lower energy expenditure compared to healthy matched controls. In addition, we will assess food intake, physical activity, and other relevant parameters.. STUDY POPULATION: 18 to 55 year old men and premenopausal women with narcolepsy and healthy matched controls. DESIGN: This is a cross-sectional, case-controlled study of ...
BACKGROUND: Several cross-sectional studies have suggested that subjects with narcolepsy have increased body mass index (BMI) and insulin resistance. These subjects exhibit a decrease in cerebrospinal fluid (CSF) orexin levels, which has been causally linked to the clinical manifestations of this disease. Orexins are peptides expressed in a brain region, the lateral hypothalamic area, which stimulate appetite and modulate sleep. Low CSF orexin levels provoke narcolepsy-like behavior, such as excessive daytime sleepiness and a sudden loss of muscle tone known as cataplexy.. OBJECTIVES: The primary objective of this study is to determine whether subjects with narcolepsy have lower energy expenditure compared to healthy matched controls. In addition, we will assess food intake, physical activity, and other relevant parameters.. STUDY POPULATION: 18 to 55 year old men and premenopausal women with narcolepsy and healthy matched controls. DESIGN: This is a cross-sectional, case-controlled study of ...
As 12 nations have reported suspected cases of narcolepsy linked to swine flu vaccination, World Health Organization scientists are saying more investigation is warranted. However, the health body has decided to keep its advice in favor of vaccination because it still believes the benefits outweigh a relatively small risk, spokeswoman Alison Brunier said, as quoted by AFP.. Concerns have been heightened since Finland, Sweden and Iceland reported an uptick in narcolepsy cases in youths between the ages of 4 and 19. Finlands National Institute for Health and Welfare says there is a link between GlaxoSmithKlines Pandemrix flu vaccine and a spike in narcolepsy cases. Narcolepsy is a disorder that causes a person to fall asleep suddenly and unexpectedly.. In a statement, the WHO points out narcolepsy is typically seen in persons who have a certain genotype. Of the cases of narcolepsy tested so far in Finland (n=22), diagnosed during 2009-2010, all have that genotype. The National Institute ...
Press release by THL, Finnish National Institute of Health and Welfare. 1 Feb 2011 http://www.thl.fi/doc/en/24103. Among those 4-19 years of age who received Pandemrix -vaccine had a manifold increased risk of falling ill with narcolepsy during the 8 months following vaccination in comparison to those unvaccinated in the same age group. Based on the evaluation done so far, the National Narcolepsy Task Force finds it probable that Pandemrix -vaccination contributed to the observed increase in incidence of narcolepsy among those 4 -19 years of age. Currently, the most likely explanation is that the increase in narcolepsy is by joint effect of the vaccine and some other factor(s). At the moment, there is no evidence that the increase in narcolepsy observed in Finland could be attributed to the vaccine lots used. The results can be read in the Interim Report of the Task Force which is published on February 1st, 2011.. The association of Pandemrix-vaccination and narcolepsy was studied using ...
Increased narcolepsy incidence was observed in Sweden following the 2009 influenza vaccination with Pandemrix(®). A substitution of the 2009 nucleoprotein for the 1934 variant has been implicated in narcolepsy development. The aims were to determine (a) antibody levels toward wild-type A/H1N1-2009[A/California/04/2009(H1N1)] (NP-CA2009) and Pandemrix-[A/Puerto Rico/8/1934(H1N1)] (NP-PR1934) nucleoproteins in 43 patients and 64 age-matched controls; (b) antibody affinity in reciprocal competitive assays in 11 childhood narcolepsy patients compared with 21 age-matched controls; and (c) antibody levels toward wild-type A/H1N1-2009[A/California/04/2009(H1N1)] (H1N1 NS1), not a component of the Pandemrix vaccine. In vitro transcribed and translated (35)S-methionine-labeled H1N1 influenza A virus proteins were used in radiobinding reciprocal competition assays to estimate antibody levels and affinity (Kd). Childhood patients had higher NP-CA2009 (p = 0.0339) and NP-PR1934 (p = 0.0246) antibody levels ...
What is the difference between narcolepsy type 1 and type 2? Learn about the role of cataplexy and testing for hypocretin levels measured in CSF.
Narcolepsy: Find the most comprehensive real-world symptom and treatment data on narcolepsy at PatientsLikeMe. 1321 patients with narcolepsy experience fatigue, anxious mood, depressed mood, pain, and excessive daytime sleepiness (somnolence) and use Modafinil, Amphetamine-Dextroamphetamine, Armodafinil, Methylphenidate, and Lisdexamfetamine to treat their narcolepsy and its symptoms.
Testing to diagnose type 1 narcolepsy. Orexin is a neuropeptide produced in the hypothalamus and is involved in the sleep/wake cycle in humans. Impairment of orexin production and orexin-modulated neurotransmission is associated with narcolepsy with cataplexy. An abnormally low concentration of orexin-A/hypocretin-1 in cerebrospinal fluid (CSF) is indicative of type 1 narcolepsy. The low CSF orexin-A/hypocretin-1 assay has over 90% sensitivity and specificity for the diagnosis of type 1 narcolepsy ...
Adrafinil is a mild stimulant of the central nervous system commonly used to prevent sleepiness in Narcolepsy patients. Narcolepsy is characterized by excessive daytime sleepiness. Adrafinil successfully combats this, and can be used in a similar way on individuals without Narcolepsy. Adrafinil is metabolized into Modafinil while passing through the body, and essentially has the same effects; such as alertness, an increase in cognitive abilities, and an increase of energy. Adrafinil does however take longer to become active due to the time it takes the metabolite to become active in the bloodstream, which is typically 45-60 minutes.. Scientists working for Group Lafon, a French pharmaceutical company, first discovered Adrafinil in the late 1970s. The drug became available in France in 1986 as an experimental treatment for narcolepsy. The same company later made Modafinil. Adrafinil is now currently marketed as Olmifon in France and Europe.. Reactions to Adrafinil vary, though often it works very ...
I started this blog in 2008 so Id have a place to record my thoughts. I have a sleep disorder called Narcolepsy, and I also have Cataplexy. The Cataplexy causes me to become weak to the point of paralysis in response to sudden emotion, most notably laughter, being startled, sudden anger, etc. This disorder has had a great impact on my life, and this blog is about how I deal with it all. Thanks for taking the time to read, and I hope you enjoy! ~ ...
Missing Neurons in Hypothalamus. The people with narcolepsy were missing neurons found in the hypothalamus region of the brain that secrete hypocretin, Siegel reported in the journal Neuron.. There are none to be seen - basically zero in the patient, Kitt said.. This tied in with findings by Dr. Emmanuel Mignot and colleagues at Stanford University, who in 1999 found that a lack of hypocretin caused narcolepsy in dogs, and who reported today they had confirmed it causes narcolepsy in people.. They also found the hypocretin-producing cells were missing in human patients.. We think that theres something that specifically kills the cells that make hypocretin. We dont know how or why, but its most likely an autoimmune disease, said Mignot, who reported the findings in the journal Nature Medicine.. Cells Attack Healthy Tissue. Siegel and Kitt agreed that an autoimmune disorder, in which the bodys immune cells mistakenly attack healthy tissue, may be to blame.. Narcolepsy can have an onset in ...
The Global Narcolepsy Therapeutics Market is expected to reach USD 3.85 billion by 2025, according to a new report by Grand View Research, Inc. The increasing awareness about this sleep disorder among public and healthcare providers is a key factor contributing to the market growth.. The Narcolepsy Network has estimated that out of every 2,000 people 1 is afflicted by this condition. Moreover, Narcolepsy UK states that around 25% patients are identified and remaining 75% are untreated as they remain undiagnosed or are misdiagnosed, which is alarming. Some organizations and networks are constantly working to spread awareness about this condition among the patients and physicians.. Full Research Report on Global Narcolepsy Therapeutics Market Analysis ...
Sleep Disorders. Narcolepsy. conventional treatment of narcolepsy include both pharmacological and non-pharmacological treatments for narcolepsy.
Understand that although media may portray a funny and characteristic picture of narcolepsy, it is rarely a laughing matter. Movies often show persons with narcolepsy going from energetic one minute to asleep the next. Generally, persons with narcolepsy will be more even-keel, instead spending most of their time extremely tired. This feeling has been compared to a normal person staying awake for three days straight and then trying to resume their normal activities. Put those shoes on and it makes it easier to understand how a person with narcolepsy consistently feels ...
Dowload Sample Page for Narcolepsy epidemiology analysis. This report contains Narcolepsy incidence/prevalence and country specific Narcolepsy treatment algorithms.
How to Manage Narcolepsy Symptoms. Narcolepsy is a neurological disorder characterized by a disruptive sleep pattern, lower quality of sleep, and excessive daytime sleepiness. Individuals suffering from narcolepsy may experience daytime...
The novel findings presented in this study are: 1) a population difference between patients with narcolepsy-cataplexy and age-matched controls with regard to hypoxic chemosensitivity; and 2) an association between DQB1*0602 and acute ventilatory responsiveness to progressive hypoxia. While narcolepsy-cataplexy patients do have different sleep values, AHI and lowest arterial ozygen saturation (Sa,O2) were not defining factors for the group differences in ventilatory chemosensitivity.. Contrary to results obtained in hypocretin gene knockout mice, hypercapnia responses were not affected by disease or marker state. Unlike knockout mice, where both the gene and protein are absent, in patients with narcolepsy, hypocretin-1 is often detected at some level in the CSF 9. We suspect that the effects of hypocretin on chemoresponsiveness, if present, are below a threshold for detection.. Our findings implicate DQB1*0602, or a gene located nearby, as a regulator of hypoxic responses. While DQB1*0602 is an ...
More than 1 million people in the U.S. have been diagnosed with Parkinsons disease, and approximately 20 million worldwide. (The percentage of those afflicted increases with age.)-- Narcolepsy affects approximately one in 2,000 individuals --- about 150,000 in the United States and 3 million worldwide. Its main symptoms are sleep attacks, nighttime sleeplessness and cataplexy, the sudden loss of skeletal muscle tone without loss of consciousness; that is, although the person cannot talk or move, they are otherwise in a state of high alertness, feeling, hearing and remembering everything that is going on around them.. When we think of Parkinsons, the first thing that comes to mind are the motor disorders associated with it, said Siegel, who is also chief of neurobiology research at the Sepulveda Veterans Affairs Medical Center in Mission Hills, Calif. But sleep disruption is a major problem in Parkinsons, often more disturbing than its motor symptoms. And most Parkinsons patients have ...
Mutations in human and/or mouse homologs are associated with this disease. Synonyms: Narcolepsy, without cataplexy; paroxysmal sleep
Narcolepsy is a sleep disorder. It is a lifelong disease of the central nervous system. Narcolepsy causes excessive and overwhelming daytime sleepiness, even after getting plenty of nighttime sleep. If you have narcolepsy, you are likely to become drowsy or to fall asleep at inappropriate times and places. These sleep attacks may happen with or without warning.
Narcolepsy is also called uncontrollable daytime sleepiness. Depressed mood and Inability to concentrate these are the main Symptoms of Narcolepsy
Narcolepsy is a disabling sleep disorder that mixes the nervous systems messages about when to sleep and when to be awake. Narcolepsy usually starts during the teen years or early adulthood and continues throughout life. Narcolepsy may cause: Sudden sleep attacks. These may occur at any time during any type of...
Do you want to know more about the most effective and available medications for narcolepsy symptoms. Well, you have come to the right place. There are, in fact, a widely scattered group of medications that can be found on different online sites.
Narcolepsy may be associated with damage to the amygdala. There is hereditary cause to the occurrence of narcolepsy. Gene that causes narcolepsy has been identified.
cord have been reported (van den Pol 1999), but even if Lower CSF hypocretin levels (hypocretin-1 levels Ͻ110 spinal release occurs, the cell bodies located in the lateral pg/mL) have been shown to be diagnostic for narcolepsy hypothalamic area are likely to be active during the active period. This would not explain the discrepancy between indicate that the time of day at which sampling is done is unlikely to interfere with this test. The data should be Hypocretins are uniquely positioned for involvement in considered preliminary because of the relatively small depression. Whereas hypocretin cell bodies are all local- number of patients and the differences in times of collec- ized within the perifornical area, extremely dense, almost tion initiation between control subjects and depressed invariably excitatory projections are noted in aminergic cell groups (e.g., adrenergic locus coeruleus, serotonergic Surprisingly, the direction of the hypocretin diurnal raphe´ nuclei, histaminergic ...
http://www.reuters.com/article/2013/05/23/us-gsk-vaccine-narcolepsy-idUSBRE94M0FJ20130523 (Reuters) - GlaxoSmithKline Plcs H1N1 pandemic flu shot may put adults at higher risk of developing narcolepsy, not only children as previous studies found, Finlands National Institute for Health and Welfare said on Thursday. Growing evidence of a link between GSKs Pandemrix vaccine and an increase in narcolepsy, a rare sleep disorder, among children…
This chapter provides an overview of the epidemiology of narcolepsy. Narcolepsy is characterized by excessive sleepiness with episodic weakness often triggered by strong emotions. Due to difficulty...
A 12 year old boy who developed narcolepsy and cataplexy after being vaccinated against swine flu at age 7 has been awarded £120 000 (€165 000; $186 000) in compensation, in a ruling that opens the way for dozens of similar awards from the United Kingdoms statutory vaccine damage compensation scheme.. Claims by the unnamed boy and dozens of others who developed the chronic neurological disorders after being given the vaccine Pandemrix during the swine flu outbreak in 2009-10 had … ...
I find it frustrating to always have to be so fucking responsible for my narcolepsy. Not only does it take time and is problematic to come to terms and fully understand ones narcolepsy and health Sometimes I just push myself beyond my limits just because I want to stay out late or/and have a good…
2019 Research Report Global Narcolepsy Market Size, Status and Forecast 2028.This report presents the worldwide Narcolepsy Market size (value, production and consumption), splits the breakdown (data status 2016-2019 and forecast to 2028), by manufacturers, region, type and application. This study also analyzes the m...
In February 2019, Mac released a new single titled "Cataplexy" and confirmed a new album is coming soon. In April, Mac ... "Cataplexy - single". iTunes Australia. Retrieved 19 April 2019. "Flamenco - single". iTunes Australia. Retrieved 19 April 2019 ...
Unlike narcolepsy with cataplexy, which has a known cause (autoimmune destruction of hypocretin-producing neurons), the cause ... This condition differs from narcolepsy in that daytime sleep periods are longer, there is no association with cataplexy, and ... The prevalence of narcolepsy (with cataplexy) is estimated between 1/3,300 and 1/5,000. Although the true prevalence of ... "Narcolepsy-cataplexy". Retrieved 2014-08-14. "Idiopathic hypersomnia". Retrieved 2014-08-14. "Primary hypersomnia epidemiology ...
The attacks of cataplexy in dogs can involve partial or full collapse. Narcolepsy with cataplexy was identified in a few breeds ... The antidepressant class is used mainly for the treatment of cataplexy, for people with narcolepsy without cataplexy these are ... differentiates between narcolepsy with cataplexy (type 1) and narcolepsy without cataplexy (type 2), while the fifth edition of ... Cataplexy is an episodic loss of muscle function, ranging from slight weakness such as limpness at the neck or knees, sagging ...
See also laughter-induced syncope, cataplexy, and Bezold-Jarisch reflex. Gelastic seizures can be due to focal lesions to the ... Totah AR, Benbadis SR (January 2002). "Gelastic syncope mistaken for cataplexy". Sleep Med. 3 (1): 77-8. doi:10.1016/S1389-9457 ... "Anomalous hypothalamic responses to humor in cataplexy". PLOS ONE. 3 (5): e2225. Bibcode:2008PLoSO...3.2225R. doi:10.1371/ ...
Unlike syncope, there is no loss of consciousness in cataplexy, which affects some sufferers of narcolepsy. To date there have ... Laughter-induced syncope should not be confused with cataplexy, a sudden loss of muscle tone triggered by strong emotions, ... "Characterizing the Emotions That Trigger Cataplexy". Journal of Neuropsychiatry and Clinical Neurosciences. American ...
Body dysmorphic disorder Cataplexy associated with narcolepsy. Which is a TGA and MHRA-labeled indication for clomipramine. ...
Vossler DG, Wyler AR, Wilkus RJ, Gardner-Walker G, Vlcek BW (May 1996). "Cataplexy and monoamine oxidase deficiency in Norrie ...
The major use of sodium oxybate is in treating two of the symptoms of narcolepsy - cataplexy (sudden muscle weakness) and ... Kane, Nancy (May 2017). "Sodium oxybate for the treatment of narcolepsy with cataplexy in adults" (PDF). NHS Regional Drug & ... Reviews of sodium oxybate concluded that it is well tolerated and associated with "significant reductions in cataplexy and ... "Narcolepsy with or without cataplexy in adults: pitolisant , Guidance and guidelines: Other Treatments". NICE. March 2017. ...
... was reported by Montplaisir and Godbout to be very effective for cataplexy in 1986, back when this was usually ... Zimelidine was able to improve cataplexy without causing daytime sleepiness. Most often reported were: Dry mouth, dryness of ... Godbout R, Montplaisir J (1986). "The effect of zimelidine, a serotonin-reuptake blocker, on cataplexy and daytime sleepiness ...
... with and without cataplexy); idiopathic hypersomnia; and recurrent hypersomnias (like Kleine-Levin syndrome). There are also ...
Cataplexy, hypnagogic hallucinations and sleep paralysis can also be present in narcolepsy. H3R antagonism leads to histamine ...
"Case Study: Cataplexy and SOREMPs Without Excessive Daytime Sleepiness in Prader Willi Syndrome. Is This the Beginning of ...
It was never approved by the FDA, but the FDA granted it an orphan designation (but not approval) for cataplexy and narcolepsy ... In narcolepsy, viloxazine has been shown to suppress auxiliary symptoms such as cataplexy and also abnormal sleep-onset REM ... In a cross-over trial (56 participants) viloxazine significantly reduced EDS and cataplexy. Viloxazine has also been studied ...
Cataplexy, on the other hand, is an involuntary loss of muscle tone during wakefulness. The mechanism of narcolepsy is unknown ...
Other scientists have also linked OBEs to cases of hypnagogia and sleep paralysis (cataplexy). In case studies fantasy ...
March 2001). "Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups". American Journal ...
"English translations of the first clinical reports on narcolepsy and cataplexy by Westphal and Gélineau in the late 19th ... He was the first physician to provide a clinical description of narcolepsy and cataplexy (1877). French physician Jean-Baptiste ...
Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP)[43]. Drug: Pitolisant ... Narcolepsy with Cataplexy, Excessive Daytime Sleepiness Comparison of Modafinil and Methylphenidate in Treatment of Excessive ... Narcolepsy, Excessive Daytime Sleepiness, Cataplexy, Sleep Disorders Dose Range Finding Study of BF2.649 Versus Placebo to ... cataplexy, and sleep apnea. Overall, the trajectory of clinical studies relating to negative symptom microsleeps seems to more ...
Cataplexy is the symptom of narcolepsy when full awareness of the environment is maintained, but all muscle tone is lost. This ... "Activity of dorsal raphe cells across the sleep-waking cycle and during cataplexy in narcoleptic dogs". J. Physiol. 554 (Pt 1 ...
Gelastic cataplexy, the sudden loss of muscle tone when the affected patient laughs, is also seen. Mutations in the SMPD1 gene ...
... cataplexy, and Parkinsonism". Frontiers in Neurology. 6 (140): 1-13. doi:10.3389/fneur.2015.00140. PMC 4478394. PMID 26157418. ... cataplexy, and Parkinsonism". Frontiers in Neurology. 6 (140): 140. doi:10.3389/fneur.2015.00140. PMC 4478394. PMID 26157418. ...
It has also been used for cataplexy, obesity, and alcohol dependence, as well as binge eating disorder. Fluoxetine seems to be ...
Cataplexy involves a sudden loss of muscle tone, and is generally precipitated by a sudden emotional response. Catatonia ...
Case Study: Cataplexy and SOREMPs Without Excessive Daytime Sleepiness in Prader Willi Syndrome. Is This the Beginning of ...
... cataplexy, and sleep apnea. Overall, the trajectory of clinical studies relating to negative symptom microsleeps seems to more ... ClinicalTrials.gov/show/NCT00620659 Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients ...
These two types are distinguished by the presence or absence of cataplexy and the cerebrospinal fluid hypocretin-1 level. ...
... but should be distinguished from similar looking attacks that may occur in cataplexy. Status epilepticus refers to continuous ...
This was also accompanied with a full stream of the first single from the record, 'A Dialogue In Cataplexy'. On September 5, ...
This drug was chosen to test because of a possible link between the causes of narcolepsy-cataplexy and AHC.[citation needed] ... Currently, sodium oxybate is used as a narcolepsy-cataplexy treatment, though in the past it has been used controversially in ...
"Case Study: Cataplexy and SOREMPs Without Excessive Daytime Sleepiness in Prader Willi Syndrome. Is This the Beginning of ...
Cataplexy without narcolepsy is rare and the cause is unknown. The term cataplexy originates from the Greek κατά (kata, meaning ... Cataplexy is treated with medications. Treatment for narcolepsy and cataplexy can be divided to those that act on the excessive ... Secondary cataplexy is associated with specific lesions located primarily in the lateral and posterior hypothalamus. Cataplexy ... Cataplexy is considered secondary when it is due to specific lesions in the brain that cause a depletion of the hypocretin ...
... loss of muscle control and hallucinations are everyday occurrences for people with narcolepsy and cataplexy. ... loss of muscle control and hallucinations are everyday occurrences for people with narcolepsy and cataplexy. ... Managing Narcolepsy and Cataplexy Naturally. In some cases, lifestyle interventions can help to manage the symptoms of ... With conditions as complex as narcolepsy and cataplexy, its strongly recommended that you seek out an expert in this area who ...
Cataplexy happens when your muscles suddenly go limp or significantly weaken without warning. Heres why it happens, other ... How is cataplexy treated?. Both cataplexy and narcolepsy with cataplexy can be treated with medication and lifestyle changes. ... How is cataplexy diagnosed?. If your doctor thinks you have narcolepsy with cataplexy, they may recommend one or more of the ... Not everyone with cataplexy has the same triggers. They may also not be consistent. Laughing may cause cataplexy in certain ...
Narcolepsy is a neurological order with symptoms like cataplexy (a debilitating condition in which a person collapses after ... Cataplexy is a sudden, temporary loss of muscle control in a person with narcolepsy. An attack of cataplexy usually is ... Medications for cataplexy. Anticataplectic medication is the general name for drugs that are used to treat cataplexy. These ... The onset of cataplexy may coincide with the onset of excessive daytime sleepiness, but cataplexy often develops years later, ...
Adrafinil is a nootropic or smart drug for mental alertness without sleep loss. Adrafinil has been used throughout Europe for decades as an effective narcolepsy treatment. It enhances mental clarity, alertness, concentration and memory. The beneficial properties of this drug are built up over a period of time, this means it can give a gentler and more... Adrafinil is a nootropic or smart... ...
Narcolepsy and Cataplexy in Dogs. 15 Sep, 2015 Dr. John McDonnell 68,573 Views ... Cataplexy is characterized by brief episodes of muscle paralysis with loss of tendon reflexes; the dog stays alert and will ... Treatment of Narcolepsy and Cataplexy in Dogs. * Primary goal is to reduce the severity and frequency of narcoleptic- ... Overview of Canine Narcolepsy and Cataplexy Narcolepsy is excessive daytime sleepiness, lethargy, or brief periods of collapse ...
Cataplexy is the sudden loss of muscle tone that is triggered by the experience of an intense emotion. The word cataplexy comes ... Cataplexy in humans is most commonly related to a lesion of the hypocretin system. In a dog model cataplexy is caused by a ... Secondary cataplexy Despite its primary association with narcolepsy, cataplexy is considered secondary when it is due to ... Cataplexy is commonly associated with narcolepsy. Primary cataplexy is a life long condition and can be disabling for the ...
Heres a description of cataplexy from wikipedia. posted by trunk muffins at 5:20 PM on June 22, 2010 [2 favorites] ... and my insurance wont pay for the sleep study necessary to diagnose narcolepsy/cataplexy, so my journey to a diagnosis is not ...
Cataplexy attacks are sudden loss of muscle tone and control, and they can have dangerous consequences as they can happen ... Most cases of cataplexy happen because a person has type 1 narcolepsy. ... People who have cataplexy must constantly be on guard to avoid injury. When an episode of cataplexy strikes, an individual may ... Cataplexy can cause muscle weakness in any part of the body, though cataplexy commonly affects the limbs (hands may drop ...
Cataplexy is a rare disorder in which a person loses muscle control when experiencing strong emotions. Find out about causes, ... Cataplexy and Other Conditions. Cataplexy vs Narcolepsy. Cataplexy is most often seen in patients who are diagnosed with ... Cataplexy: What Does It Mean?. Cataplexy is a partial or generalized loss of muscle tone or control that is triggered by ... Possible Medications for Cataplexy. Sodium oxybate is a medication approved by the FDA for use in cataplexy. It is thought to ...
Does everyone with narcolepsy have cataplexy?. It is thought that about 75% of patients with narcolepsy experience cataplexy. ... When cataplexy is present, it is extremely rare for it to be an isolated symptom - the vast majority of those with typical ... Cataplexy attacks generally last less than two minutes, and they may only last a few seconds, though some people have repeated ... Cataplexy may be most severe when the person with narcolepsy is tired rather than fully alert, and can lead to considerable ...
Woman sleep number bed commercial Sleep apnea and death statistics Cataplexy causes symptoms Stop snoring mouthpiece tongue ...
cognitive behavioral therapy techniques for depression, what causes sleep talking nhs, cpap machines for sleep apnoea, sleep diary template excel, snoring early pregnancy, child insomnia melatonin, national sleep foundation pillow, how to beat jet lag from asia
About Cataplexy Cataplexy, the most specific symptom of narcolepsy, is the sudden, generally brief (,2 minutes) loss of muscle ... Xywav, also known as JZP-258, is approved by the U.S. Food and Drug Administration (FDA) for the treatment of cataplexy or ... Narcolepsy is a life-long condition so it is important to have new options to help treat EDS and cataplexy. ... Xywav is the first FDA approved new treatment option indicated for both cataplexy and excessive daytime sleepiness in people ...
Because a recent work on canine narcolepsy suggests that the mechanisms for triggering cataplexy are dif … ... Cataplexy, an abnormal manifestation of REM sleep atonia, is currently treated with antidepressants. These medications also ... Sulpiride, a D2/D3 blocker, reduces cataplexy but not REM sleep in canine narcolepsy Neuropsychopharmacology. 2000 Nov;23(5): ... Cataplexy, an abnormal manifestation of REM sleep atonia, is currently treated with antidepressants. These medications also ...
Unilateral cataplexy has not been described previously in detail and its association with SLE is unique. The clinical details, ... A patient with systemic lupus erythematosus (SLE) developed attacks of unilateral cataplexy precipitated by laughter. ... investigations, and diagnostic criteria are discussed and a causal relationship between cataplexy and SLE is suggested. ...
... cataplexy explanation free. What is cataplexy? Meaning of cataplexy medical term. What does cataplexy mean? ... Looking for online definition of cataplexy in the Medical Dictionary? ... cataplexy. (kăt′ə-plĕk′sē). n. pl. cataplex·ies A sudden loss of muscle tone and strength, usually caused by an extreme ... cataplexy. Also found in: Dictionary, Encyclopedia, Wikipedia. cataplexy. [kat´ah-plek″se] a condition, often associated with ...
TOPIC: Cataplexy metabolism, forming primary, reflexes, operation. Cataplexy metabolism, forming primary, reflexes, operation. ...
Ventilatory chemoresponsiveness, narcolepsy-cataplexy and human leukocyte antigen DQB1*0602 status. F. Han, E. Mignot, Y.C. Wei ... Ventilatory chemoresponsiveness, narcolepsy-cataplexy and human leukocyte antigen DQB1*0602 status. F. Han, E. Mignot, Y.C. Wei ... Ventilatory chemoresponsiveness, narcolepsy-cataplexy and human leukocyte antigen DQB1*0602 status. F. Han, E. Mignot, Y.C. Wei ... While narcolepsy-cataplexy patients do have different sleep values, AHI and lowest arterial ozygen saturation (Sa,O2) were not ...
Ali on medicine for cataplexy: If the medicine gave you the best results discuss with your prescribing physician the dose ... Can you tell me what to expect with symptoms of cataplexy when I am very scaredwith the possibility of it being cataplexy? ... It looks like cataplexy, but i dont have other narcolepsy symptoms. Can it be cataplexy without n.? ... Cataplexy attacks: Cataplexy attacks = sudden onset but brief bouts of marked muscle weakness which can cause someone to ...
In contrast, cataplexy a pathognomonic symptom of narcolepsy - is caused by the involuntary onset of REM-like atonia during ... Control of motoneuron function and muscle tone during REM sleep, REM sleep behavior disorder and cataplexy/narcolepsy Arch Ital ... and cataplexy/narcolepsy. For example, RBD is characterized by dramatic REM motor activation resulting in dream enactment and ... responsible for the loss of postural muscle tone during cataplexy in narcoleptic mice. Together, this research indicates that ...
Role of the medial prefrontal cortex in cataplexy ... Narcolepsy with cataplexy is caused by a loss of orexin (also ... Role of the medial prefrontal cortex in cataplexy. Role of the medial prefrontal cortex in cataplexy. Oishi, Y.; Williams, R.H ... These observations indicate that the mPFC is a critical site through which positive emotions trigger cataplexy. (PDF emailed ... Narcolepsy is characterized by chronic sleepiness and cataplexy, episodes of profound muscle weakness that are often triggered ...
... and cataplexy (minimum of 3 complete or partial cataplexy attacks per week). ... Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP). The safety and ... Narcolepsy With Cataplexy Excessive Daytime Sleepiness Drug: Pitolisant Drug: Placebo Phase 3 ... Cataplexy. Disorders of Excessive Somnolence. Sleep Disorders, Intrinsic. Dyssomnias. Sleep Wake Disorders. Nervous System ...
Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy ... Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy Brief description of study. The ... this study is to determine whether FT218 is safe and effective for the treatment of excessive daytime sleepiness and cataplexy ...
Narcolepsy Cataplexy Other: fMRI Other: Videopolysomnography Other: NC (narcolepsy-cataplexy) Not Applicable ... Other: NC (narcolepsy-cataplexy) The investigators hypothesize that NC patients with RBD have a more severe dysfunction of the ... Cataplexy. Disorders of Excessive Somnolence. Sleep Disorders, Intrinsic. Dyssomnias. Sleep Wake Disorders. Nervous System ... Exploration of the Reward System by Functional MRI in Narco-cataplexy Patients With and Without REM Sleep Behavior Disorder (NC ...
Suspected episodes of cataplexy have been reported in eight of 35,1 four of 25,2 and three of 173 patients with PWS. However, ... We suggest that cataplexy may be relatively common in PWS and enquiries regarding its signs should always be made, especially ... Episodes of cataplexy and of narcolepsy, despite excellent weight control, have been reported by two other patients with PWS ... We report cataplexy, sudden atonic episodes provoked by emotion, in three patients with Prader-Willi syndrome (PWS) and suggest ...
Pitolisant: A Review in Narcolepsy with or without Cataplexy.. Jan 31, 2020 ... for the treatment of narcolepsy with or without cataplexy in adults and in the USA (as of August 2019) for the treatment of ... suggests that pitolisant administered at up to the recommended maximum dose of 36 mg once daily reduces EDS and cataplexy in ... extends the range of approved treatment options available to adult patients with narcolepsy with or without cataplexy. ...
... placebo-controlled trial to evaluate sodium oxybate for the treatment of children and adolescents with narcolepsy and cataplexy ... First Study to Evaluate Sodium Oxybate in Peds With Narcolepsy, Cataplexy * Share on Facebook ... The target enrollment is a minimum of 100 patients who have a primary diagnosis of narcolepsy with cataplexy. Patients will be ... The primary outcome efficacy measure is change in weekly number of cataplexy attacks, evaluated using a daily diary. For safety ...
... improved excessive sleepiness in patients with narcolepsy both with and without cataplexy, results of a retrospective analysis ... The patients were adults with narcolepsy with cataplexy (n=95) or without cataplexy (n=127). Patients with cataplexy "were ... The Effects of Sodium Oxybate on Patients With Narcolepsy Without Cataplexy Da Hee Han, PharmD ... In patients with narcolepsy and cataplexy, ESS improvement was significantly greater with sodium oxybate (-2.9; P=0.011) and ...
To assess the quality of life of patients with narcolepsy with cataplexy (NA-CA), narcolepsy without cataplexy (NA w/o CA), and ... Quality of life in patients with narcolepsy with cataplexy, narcolepsy without cataplexy, and idiopathic hypersomnia without ...
  • Cataplexy manifests itself as muscular weakness which may range from a barely perceptible slackening of the facial muscles to complete muscle paralysis with postural collapse. (wikipedia.org)
  • Symptoms include excessive daytime sleepiness (EDS), sudden loss of muscle tone (cataplexy), distorted perceptions (hypnagogic hallucinations), inability to move or talk ( sleep paralysis ), disturbed nocturnal sleep , and automatic behavior. (rxlist.com)
  • Anticataplectic medications are used to treat cataplexy, hypnagogic hallucinations, and sleep paralysis. (rxlist.com)
  • This additional symptom, along with excessive daytime sleepiness and the REM related abnormalities (cataplexy, hypnagogic hallucinations, and sleep paralysis), from the so-called 'narcolepsy pentad' (a set of five symptoms). (rxlist.com)
  • She had no history of the sleep paralysis or hypnagogic hallucinations and there was no family history of cataplexy, narcolepsy, or epilepsy. (bmj.com)
  • Additional symptoms may include cataplexy, hypnagogic hallucinations, and sleep paralysis . (medicalnewstoday.com)
  • Cataplexy - may mimic drop attacks , syncope, seizures/epilepsy, transient ischaemic attack, periodic paralysis (channelopathies), psychiatric disorder, or cataplectic-like episodes (the latter can occur in healthy people). (symptoma.com)
  • Cataplexy is akin to sleep paralysis that happens during REM sleep, but it does not cause unconsciousness. (medic8.com)
  • Severe cataplexy can cause total paralysis and potential falls. (medic8.com)
  • Cataplexy is a sudden and uncontrollable muscle weakness or paralysis that comes on during the day. (everydayhealth.com)
  • Narcolepsy is a neurological disorder characterized by excessive sleepiness, sleep paralysis, hallucinations, and in some cases episodes of cataplexy. (everydayhealth.com)
  • Cataplexy, sleep paralysis, and hypnagogic hallucinations are similar to the loss of muscle tone that accompanies normal dreaming in a stage of sleep called REM. (chop.edu)
  • The four most common symptoms are: excessive daytime sleepiness, cataplexy, sleep paralysis, and hypnagogic hallucinations. (chop.edu)
  • Unlike cataplexy, touching the person usually causes the paralysis to disappear. (chop.edu)
  • The disorder is defined by persistent drowsiness throughout the day, and in some cases, sleep paralysis, hallucinations, and the sudden loss of muscle control known as cataplexy. (mentalfloss.com)
  • Cataplexy, according to the Sleep Foundation, is a "sudden and uncontrollable muscle weakness or paralysis that comes on during the day and is often triggered by a strong emotion, such as excitement or laughter. (universityhealthnews.com)
  • Narcolepsy is a disorder which typically begins with excessive daytime sleepiness during the second and third decades of life, progressing to include disturbed night-time sleep, cataplexy, sleep paralysis and hypnagogic hallucinations (hallucinations while falling asleep). (hospitalpharmacyeurope.com)
  • Narcolepsy and cataplexy are uncommon disorders of the sleep mechanism in which a dog is excessively sleepy all day (narcolepsy) or experiences sudden muscle paralysis and collapse (cataplecy). (wiki-pet.com)
  • Antidepressant medicines can help reduce episodes of cataplexy, sleep paralysis, and hallucinations. (medlineplus.gov)
  • Sleep paralysis, hypnagogic/hypnopompic hallucinations, and cataplexy-like symptoms: Risk increases with dose ( 5.6 ). (nih.gov)
  • Three additional symptoms often associated with narcolepsy are sudden extreme muscle weakness (cataplexy), a specific type of hallucination that occurs just before falling asleep or upon awakening, and brief episodes of paralysis while waking up. (webmd.com)
  • Together these result in the symptom complex of excessive daytime sleepiness accompanied by irresistible "sleep attacks," cataplexy, sleep-onset hallucinations, and sleep paralysis. (elsevier.com)
  • Narcolepsy-cataplexy is a chronic neurological disorder caused by loss of orexin (hypocretin)-producing neurons, associated with excessive daytime sleepiness, sleep attacks, cataplexy, sleep paralysis, hypnagogic hallucinations, and fragmentation of nighttime sleep. (elsevier.com)
  • Cataplexy is basically sleep paralysis. (medhelp.org)
  • citation needed] Cataplexy attacks are self-limiting and resolve without the need for medical intervention. (wikipedia.org)
  • While cataplexy worsens with fatigue, it is different from narcoleptic sleep attacks and is usually, but not always, triggered by strong emotional reactions such as laughter, anger, surprise, awe, and embarrassment, or by sudden physical effort, especially if the person is caught off guard. (wikipedia.org)
  • Cataplexy attacks generally last less than two minutes, and they may only last a few seconds, though some people have repeated attacks of cataplexy which persist for up to 30 minutes. (narcolepsy.org.uk)
  • 0.0001) in weekly number of cataplexy attacks and Epworth Sleepiness Scale scores compared to placebo. (prnewswire.com)
  • A patient with systemic lupus erythematosus (SLE) developed attacks of unilateral cataplexy precipitated by laughter. (bmj.com)
  • New onset cataplexy attacks. (healthtap.com)
  • Cataplexy attacks can be mistaken for seizures. (healthtap.com)
  • What is the definition or description of: Cataplexy attacks? (healthtap.com)
  • Cataplexy attacks = sudden onset but brief bouts of marked muscle weakness which can cause someone to collapse. (healthtap.com)
  • Double blind, randomized, parallel groups study of Pitolisant versus placebo, in narcoleptic patients experiencing EDS, and cataplexy (minimum of 3 complete or partial cataplexy attacks per week). (clinicaltrials.gov)
  • The treatment period (7 weeks double blind) will aim at demonstrating the efficacy of Pitolisant on the number of cataplexy attacks and the Excessive Daytime Sleepiness by verifying whether the results of Pitolisant are superior to those of placebo. (clinicaltrials.gov)
  • A Randomized, Double Blind Study Comparing Pitolisant (BF2.649) to Placebo in Two Parallel Groups on the Weekly Frequency of Cataplexy Attacks and Excessive Daytime Sleepiness in Narcoleptic Patients With Cataplexy. (clinicaltrials.gov)
  • Measure of anticataplectic efficacy assessed by the change in the average number of cataplexy attacks per week. (clinicaltrials.gov)
  • The primary outcome efficacy measure is change in weekly number of cataplexy attacks, evaluated using a daily diary. (empr.com)
  • It also features abnormal rapid eye movement ( REM ) sleep and it can involve cataplexy, brief attacks of muscle weakness and tone that can lead to body collapse. (medicalnewstoday.com)
  • His recently developed ' drop attacks ' on laughter were recognized as cataplexy and led to the diagnosis of Niemann-Pick type C disease. (symptoma.com)
  • Patients maintained on XYREM at established dosages experienced no median change in the number of cataplexy attacks. (xyremhcp.com)
  • Attacks of cataplexy are sudden, brief losses of muscle control. (chop.edu)
  • Cataplexy attacks may occur at anytime, and because the victim remains conscious, should not be confused with seizures. (hubpages.com)
  • A study in 2006 in "Tohoku Journal of Experimental Medicine" concluded that the neurochemical hypocretin, which is regulated by the hypothalamus, was significantly reduced in study participants with symptoms of cataplexy. (wikipedia.org)
  • Keep reading to learn more about the symptoms of cataplexy, what causes it, and more. (healthline.com)
  • Symptoms of cataplexy can be different for each person. (healthline.com)
  • Cataplexy can be one of the first noticeable symptoms in people who have narcolepsy. (healthline.com)
  • However, as many as 10 percent of those with narcolepsy and cataplexy have close relatives who show symptoms of these conditions. (healthline.com)
  • Cataplexy may appear before symptoms of narcolepsy. (rxlist.com)
  • In some cases, type 2 narcolepsy - the one without cataplexy, which has milder symptoms - may develop into narcolepsy with cataplexy, says Eric Olson, MD , an associate professor of medicine and sleep medicine specialist at the Mayo Clinic in Rochester, Minnesota, and a board member of the American Academy of Sleep Medicine. (everydayhealth.com)
  • Cataplexy is a rare disorder in which a person loses muscle control when experiencing strong emotions (also one of the symptoms of narcolepsy). (depressionalliance.org)
  • Those who suffer from cataplexy can feel isolated as they tend to withdraw from emotionally charged situations in order to manage their symptoms. (depressionalliance.org)
  • Not all people with narcolepsy have cataplexy symptoms. (depressionalliance.org)
  • Likewise, not all patients who suffer from cataplexy symptoms are diagnosed with narcolepsy. (depressionalliance.org)
  • Rarely, other medical conditions including stroke, multiple sclerosis, antidepressant withdrawal, and genetic disorders can also be associated with symptoms of cataplexy. (depressionalliance.org)
  • While cataplexy and catatonia can present with similar symptoms, they are two very different conditions. (depressionalliance.org)
  • When cataplexy is present, it is extremely rare for it to be an isolated symptom - the vast majority of those with typical cataplexy will also have symptoms of narcolepsy. (narcolepsy.org.uk)
  • What are the symptoms of cataplexy? (healthtap.com)
  • Can you tell me what to expect with symptoms of cataplexy when I am very scaredwith the possibility of it being cataplexy? (healthtap.com)
  • More detailed information about the symptoms , causes , and treatments of Narcolepsy with cataplexy is available below. (rightdiagnosis.com)
  • Other prominent symptoms like muscle weakness, hallucinations, and cataplexy might take years to develop. (redorbit.com)
  • People with NT2 have many similar symptoms as people with NT1, but they do not have cataplexy or low levels of hypocretin-1. (sleepfoundation.org)
  • It is not an inherited condition, even though up to 10 percent of those with cataplexy have close relatives who show symptoms. (universityhealthnews.com)
  • I was first diagnosed with RLS then Narcolepsy (I have cataplexy, and all the other symptoms) I am on Xyrem-the new drug from Orphan. (rls.org)
  • Cataplexy is one of the most pathognomonic symptoms in narcolepsy. (cdc.gov)
  • XYREM is approved to treat 2 common symptoms of narcolepsy: excessive daytime sleepiness (EDS) and cataplexy. (xyrem.com)
  • Educate yourself about XYREM and how it may help with your narcolepsy symptoms of EDS and cataplexy. (xyrem.com)
  • The Doctor Discussion Guide gives you some useful information about the symptoms of cataplexy and EDS in narcolepsy and XYREM. (xyrem.com)
  • The main target of this review is to discuss symptomatic pharmacological treatments and behavioral and psychosocial interventions for EDS and cataplexy in adulthood and childhood and the core narcolepsy symptoms, in order to help clinicians in their clinical practice. (springer.com)
  • Although there is no cure for narcolepsy, the most disabling symptoms of the disorder (EDS and symptoms of abnormal REM sleep, such as cataplexy) can be controlled in most people with drug treatment. (webmd.com)
  • If you have narcolepsy, it's likely that you'll experience an episode of cataplexy at some point in your life. (healthline.com)
  • When an episode of cataplexy strikes, an individual may slump, lose his or her grip on something, or fall down. (everydayhealth.com)
  • Can you have only one episode of cataplexy and then never have it again? (healthtap.com)
  • During an episode of cataplexy, an individual is awake but temporarily paralyzed. (everydayhealth.com)
  • Xyrem®) has been approved in most countries for treatment of narcolepsy and cataplexy. (uzh.ch)
  • Xyrem (sodium oxybate) oral solution is indicated for the treatment of cataplexy in narcolepsy . (medicinenet.com)
  • XYREM ® is indicated for the treatment of cataplexy in narcolepsy. (xyremhcp.com)
  • Did Xyrem help your cataplexy? (rls.org)
  • According to a report by Pharmalive, the European Commission has approved sodium oxybate (Xyrem®) for treating narcolepsy with cataplexy in adult patients. (hospitalpharmacyeurope.com)
  • XYREM is the only available FDA-approved treatment for both cataplexy and EDS in narcolepsy in both children and adults, and the only FDA-approved treatment for cataplexy. (xyrem.com)
  • Sodium oxybate (Xyrem) works well to control cataplexy. (medlineplus.gov)
  • Cataplexy is a sudden and transient episode of muscle weakness accompanied by full conscious awareness, typically triggered by emotions such as laughing, crying, or terror. (wikipedia.org)
  • Cataplexy - episodes of uncontrollable muscle weakness - typically last a few seconds to a few minutes, and can happen as infrequently as a few times a year or as often as a few times a day. (everydayhealth.com)
  • Cataplexy can cause muscle weakness in any part of the body, though cataplexy commonly affects the limbs (hands may drop whatever they're holding, knees may buckle, legs may collapse) and face (eyelids may droop, jaw may go slack and speech become slurred, the head may nod). (everydayhealth.com)
  • Narcolepsy is characterized by chronic sleepiness and cataplexy, episodes of profound muscle weakness that are often triggered by strong, positive emotions. (eurekamag.com)
  • Narcolepsy refers to excessive sleepiness and cataplexy refers to the sudden onset of muscle weakness in the face, legs or arms. (rightdiagnosis.com)
  • Cataplexy is a sudden muscle weakness in the face, neck, and knees. (medicalnewstoday.com)
  • A sudden , temporary period of muscle weakness in fully-conscious people is called cataplexy. (symptoma.com)
  • Typically, cataplexy does not develop for months or even years after the first signs of excessive daytime sleepiness, but in rare cases it is the first observed symptom of narcolepsy. (narcolepsy.org.uk)
  • In contrast, cataplexy a pathognomonic symptom of narcolepsy - is caused by the involuntary onset of REM-like atonia during wakefulness. (nih.gov)
  • Cataplexy has been a dangerous symptom of Narcolepsy. (sleep-disorders.net)
  • Cataplexy is sometimes the first symptom of narcolepsy, but usually it develops several years after EDS. (chop.edu)
  • We previously demonstrated that orexin neurons inhibit cataplexy-like episodes-cataplexy is a cardinal symptom of narcolepsy, characterized by a sudden weakening of muscle tone-via serotonin neurons in the dorsal raphe nucleus (DRN). (pnas.org)
  • While it is not known how many people suffer from cataplexy, narcolepsy is thought to affect as many as 200,000 people in the United States. (depressionalliance.org)
  • People who suffer from cataplexy and catatonia can both have trouble with muscle movement or control, and they often have a lack of response to any external stimuli during their episodes. (depressionalliance.org)
  • It's worth noting that people with low hypocretin have type 1 narcolepsy even if they don't suffer from cataplexy. (redorbit.com)
  • Around three quarters of persons with narcolepsy suffer from cataplexy, which causes the muscles to become weak. (medic8.com)
  • The purpose of this study is to determine whether FT218 is safe and effective for the treatment of excessive daytime sleepiness and cataplexy in subjects with narcolepsy. (centerwatch.com)
  • Most people with narcolepsy have daytime sleepiness and cataplexy. (medlineplus.gov)
  • Although cataplexy is most often associated with narcolepsy, it has also been associated with stroke , multiple sclerosis , head injuries, and encephalitis . (universityhealthnews.com)
  • Cataplexy affects approximately 70% of people who have narcolepsy, and is caused by an autoimmune destruction of hypothalamic neurons that produce the neuropeptide hypocretin (also called orexin), which regulates arousal and has a role in stabilization of the transition between wake and sleep states. (wikipedia.org)
  • If you have narcolepsy with cataplexy, your brain doesn't have enough hypocretin (orexin). (healthline.com)
  • Cataplexy is the result of an absence of the hypocretin (also known as orexin) neurotransmitter in the hypothalamus . (scholarpedia.org)
  • Narcolepsy with cataplexy is caused by a loss of orexin (also known as hypocretin) signaling, but almost nothing is known about the neural mechanisms through which positive emotions trigger cataplexy. (eurekamag.com)
  • Using orexin knock-out mice as a model of narcolepsy, we found that palatable foods, especially chocolate, markedly increased cataplexy and activated neurons in the medial prefrontal cortex (mPFC). (eurekamag.com)
  • We therefore propose that the orexin neuron-DRN serotonin neuron-amygdala pathway is a critical circuit for preventing cataplexy. (pnas.org)
  • Narcolepsy is a sleep disorder caused by the loss of orexin (hypocretin)-producing neurons and marked by excessive daytime sleepiness and a sudden weakening of muscle tone, or cataplexy, often triggered by strong emotions. (pnas.org)
  • In a mouse model for narcolepsy, we previously demonstrated that serotonin neurons of the dorsal raphe nucleus (DRN) mediate the suppression of cataplexy-like episodes (CLEs) by orexin neurons. (pnas.org)
  • Among people who have narcolepsy and cataplexy, there is a loss of brain cells that produce hypocretin , also called orexin, a neurotransmitter that controls the sleep/wake cycle. (universityhealthnews.com)
  • Willie, JT & Yanagisawa, M 2006, Lessons from sleepy mice: Narcolepsy-cataplexy and the orexin neuropeptide system . (elsevier.com)
  • Cataplexy and sleep-onset REM sleep were significantly decreased in orexin knockout mice during and long after slow infusion of orexin (1 nmol/1 μL/h). (elsevier.com)
  • This study supports the concept of intrathecal orexin delivery as a potential therapy for narcolepsy-cataplexy to improve the well-being of patients. (elsevier.com)
  • We report cataplexy, sudden atonic episodes provoked by emotion, in three patients with Prader-Willi syndrome (PWS) and suggest that cataplexy may be relatively common in this condition. (bmj.com)
  • Episodes of cataplexy and of narcolepsy, despite excellent weight control, have been reported by two other patients with PWS who attend this hospital, an 8 year old girl and a 10 year old boy. (bmj.com)
  • Suspected episodes of cataplexy have been reported in eight of 35, 1 four of 25, 2 and three of 17 3 patients with PWS. (bmj.com)
  • We thus used optogenetic and chemogenetic approaches to demonstrate that DRN serotonin neurons suppress cataplexy-like episodes by reducing the activity of the amygdala that plays an important role in emotional processing, as consistent with the fact that strong emotions often trigger cataplexy. (pnas.org)
  • Not all patients who are diagnosed with NT1 experience episodes of cataplexy. (sleepfoundation.org)
  • A cataplexy patient's medical history and description of possible cataplectic episodes are important for an accurate diagnosis. (universityhealthnews.com)
  • The drug approved by the U.S. Food & Drug Administration specifically for the treatment of cataplexy is sodium oxybate, which has been shown to reduce the frequency and severity of episodes. (universityhealthnews.com)
  • The results of these tests should be normal if narcolepsy/cataplexy is the presumptive diagnosis. (petplace.com)
  • Whilst there are a few neurodevelopmental conditions in which a form of cataplexy may be seen, those conditions are exceedingly rare, and so the occurrence of cataplexy generally makes diagnosis of narcolepsy much more certain. (narcolepsy.org.uk)
  • Diagnosis of narcolepsy with cataplexy was made using International Classification of Sleep Disorders (ICSD)-II criteria 14 . (ersjournals.com)
  • We suggest that cataplexy may be relatively common in PWS and enquiries regarding its signs should always be made, especially in any patient with a past diagnosis of paroxysmal events. (bmj.com)
  • The target enrollment is a minimum of 100 patients who have a primary diagnosis of narcolepsy with cataplexy. (empr.com)
  • Even when not present at diagnosis, cataplexy eventually occurs in a significant number of people with low levels of hypocretin-1. (sleepfoundation.org)
  • If a person with NT2 later develops cataplexy or low hypocretin-1 levels, their diagnosis can be reclassified as NT1. (sleepfoundation.org)
  • Data from the Stanford University Sleep Disorders Clinic of 200 patients with cataplexy showed that 100 percent of these patients reported laughter as the most common trigger, followed by a feeling of amusement, or surprise with happiness and joy [2]. (scholarpedia.org)
  • These observations indicate that the mPFC is a critical site through which positive emotions trigger cataplexy. (eurekamag.com)
  • Emotions such as laughter, elation and anger can trigger cataplexy. (patient.info)
  • 5. Strong emotions can trigger cataplexy. (mentalfloss.com)
  • JAZZ ) today announced that the U.S. Food and Drug Administration (FDA) approved Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution on July 21 , 2020 for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. (prnewswire.com)
  • Sodium oxybate carries warnings about its high sodium content, 10 and was previously the only product approved to treat both cataplexy and EDS in patients with narcolepsy 7 years of age and older 11 and designated as a standard of care for the treatment of cataplexy and EDS by the American Academy of Sleep Medicine. (prnewswire.com)
  • SEATTLE, WA -The first formal randomized, placebo-controlled trial to evaluate sodium oxybate for the treatment of children and adolescents with narcolepsy and cataplexy is currently enrolling patients ( NCT02221869 ), investigators reported at SLEEP 2015. (empr.com)
  • Sodium oxybate is approved for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adults with narcolepsy and is recommended by the American Academy of Sleep Medicine as standard care for EDS and cataplexy in patients with narcolepsy. (empr.com)
  • The primary objective of the 52-week double-blind withdrawal trial is to evaluate the efficacy and safety of sodium oxybate for the treatment of cataplexy in patients 7-17 years of age with narcolepsy with cataplexy. (empr.com)
  • Data will help determine the efficacy benefits and will help identify safety issues associated with sodium oxybate treatment in children in children and adolescents with narcolepsy with cataplexy," Dr. Wang noted. (empr.com)
  • More patients with narcolepsy without cataplexy treated with sodium oxybate (44.1%) and sodium oxybate +modafinil (41.4%) achieved "very much improved" or "much improved" on the CGI-C vs placebo (28.6%), but these differences were not statistically significant, Dr. Black added. (empr.com)
  • Background Sodium oxybate is licensed in Europe for the treatment of narcolepsy with cataplexy in adults. (kcl.ac.uk)
  • The aim of this study was to assess the efficacy and safety of sodium oxybate in clinical practice in patients with narcolepsy and cataplexy refractory to other treatments. (kcl.ac.uk)
  • Materials and methods This was a retrospective single centre study including patients with severe narcolepsy with cataplexy refractory to other treatments, who were initiated on sodium oxybate between 2009-2015. (kcl.ac.uk)
  • Conclusions Sodium oxybate provides a good clinical efficacy and acceptable safety profile in routine clinical practice for the treatment of patients suffering from narcolepsy with cataplexy. (kcl.ac.uk)
  • Cataplexy occurs in some children and adults with narcolepsy, and more rarely can be associated with other disorders. (depressionalliance.org)
  • Pitolisant (Wakix), an orally available, first-in-class antagonist/inverse agonist of the histamine 3 receptor, is approved in the EU (as of March 2016) for the treatment of narcolepsy with or without cataplexy in adults and in the USA (as of August 2019) for the treatment of excessive daytime sleepiness (EDS) in adults with narcolepsy. (physiciansweekly.com)
  • The totality of evidence from pivotal and supportive phase III trials suggests that pitolisant administered at up to the recommended maximum dose of 36 mg once daily reduces EDS and cataplexy in adults with narcolepsy relative to placebo. (physiciansweekly.com)
  • The patients were adults with narcolepsy with cataplexy (n=95) or without cataplexy (n=127). (empr.com)
  • Cataplexy is the sudden loss of muscle tone that is triggered by the experience of an intense emotion . (scholarpedia.org)
  • The sudden loss of muscle tone in cataplexy is similar to rapid eye movement (REM)-associated muscle atonia during sleep, but it is occurring during wakefulness. (scholarpedia.org)
  • The cataplexy involves a sudden loss of muscle tone and collapse with intense emotions, such as crying or laughing. (healthtap.com)
  • Cataplexy is the sudden loss of muscle tone often triggered by strong emotions such as laughter , surprise, crying . (healthtap.com)
  • In cataplexy you have sudden loss of control over some of your muscles. (patient.info)
  • Sudden loss of muscle control is called cataplexy, and it's the defining symptom of type 1 narcolepsy. (mentalfloss.com)
  • NT1 is associated with the symptom of cataplexy, which is the sudden loss of muscle tone. (sleepfoundation.org)
  • The answer is cataplexy-a sudden loss of muscle strength, tone, and control. (universityhealthnews.com)
  • Cataplexy also occurs more frequently in times of emotional stress and when patients are deprived of napping while sleepy. (scholarpedia.org)
  • A review of 100 patients with cataplexy at the Stanford Sleep Disorders Clinic (age range 12-20 years) reported that 62 of these patients stopped taking anti-cataplectic medications after 10 years [2]. (scholarpedia.org)
  • Without specific diagnostic criteria for cataplexy, it can be challenging to diagnose patients with this condition. (depressionalliance.org)
  • It is thought that about 75% of patients with narcolepsy experience cataplexy. (narcolepsy.org.uk)
  • The FDA approval of Xywav is based on a global Phase 3 double-blind, placebo-controlled, randomized-withdrawal, multicenter study that demonstrated the efficacy and safety of Xywav in the treatment of cataplexy and EDS in patients with narcolepsy. (prnewswire.com)
  • Hypocretin is a recently-defined neuropeptide and its levels in CSF have been found low in approximately 90% of patients with idiopathic narcolepsy and cataplexy (8). (thefreedictionary.com)
  • 130 patients with narcolepsy/hypocretin deficiency and/or cataplexy were prospectively identified from successive patients presenting at the Sleep Center, the Peking University People's Hospital (Beijing, China) in 2006-2007. (ersjournals.com)
  • All patients completed a validated questionnaire predictive of cataplexy, the Center for Narcolepsy Sleep Inventory (SSI), a validated questionnaire predictive of cataplexy 15 . (ersjournals.com)
  • Up to 50% of Narcolepsy-cataplexy (NC) patients suffer from REM sleep behavior disorder (RBD), a parasomnia. (clinicaltrials.gov)
  • Only one of the three patients possesses the HLA DR15 (DR2) DQB1*0602 haplotype that is strongly associated with the narcolepsy-cataplexy syndrome. (bmj.com)
  • With minimal abuse potential and offering the convenience of oral, once-daily administration, pitolisant extends the range of approved treatment options available to adult patients with narcolepsy with or without cataplexy. (physiciansweekly.com)
  • Jazz), alone or in combination with modafinil, improved excessive sleepiness in patients with narcolepsy both with and without cataplexy, results of a retrospective analysis of Phase 3 randomized trial data presented at SLEEP 2015 has found. (empr.com)
  • Patients with cataplexy "were identified based on medical history, concomitant medications, and sleep-onset rapid eye movement (REM) periods on the nocturnal polysomnogram," Dr. Black said. (empr.com)
  • Quality of life in patients with narcolepsy with cataplexy, narcolepsy without cataplexy, and idiopathic hypersomnia without long sleep time: comparison between patients on psychostimulants, drug-naïve patients and the general Japanese population. (sigmaaldrich.com)
  • To assess the quality of life of patients with narcolepsy with cataplexy (NA-CA), narcolepsy without cataplexy (NA w/o CA), and idiopathic hypersomnia without long sleep time (IHS w/o LST) who were taking psychostimulant medication, and to ascertain which factors (including psychosocial and environmental variables) influence quality of life in this population. (sigmaaldrich.com)
  • Eighteen patients with idiopathic hypersomnia (IH) were compared with 50 patients with the narcoleptic syndrome of cataplexy and daytime sleepiness (NLS) using self report questionnaires and a diary of sleep/wake patterns. (bmj.com)
  • In this study, we present a single-center experience of a series of 18 patients with narcolepsy with cataplexy (18/18 DQB1*0602 positive, 17/17 with low/absent cerebrospinal fluid hypocretin) in whom SO was prescribed. (uzh.ch)
  • Extensive HLA class II studies in 58 non-DRB1*15 (DR2) narcoleptic patients with cataplexy. (semanticscholar.org)
  • In this study, 58 non-DR15 patients with narcolepsy-cataplexy were typed at the HLA DRB1, DQA1 and DQB1 loci. (semanticscholar.org)
  • This type of narcolepsy includes cataplexy and low CSF hypocretin-1 levels - some patients might have no hypocretin at all. (redorbit.com)
  • Some of the doses estimated to be abused are in a similar dosage range to that used for treatment of patients with cataplexy. (medicinenet.com)
  • Because illicit use and abuse of GHB have been reported, physicians should carefully evaluate patients for a history of drug abuse and follow such patients closely, observing them for signs of misuse or abuse of GHB (e.g. increase in size or frequency of dosing, drug-seeking behavior, feigned cataplexy). (medicinenet.com)
  • The patients were divided into a narcolepsy with cataplexy group (n=56) and a narcolepsy without cataplexy group (n=16). (cdc.gov)
  • In cataplexy-positive patients, as compared with cataplexy-negative patients, the frequency of HLA-DQB1*0602 was found to be significantly high (89.3% vs. 50.0%) (p=0.003). (cdc.gov)
  • Results from a phase 3 controlled trial show that pitolisant (Wakix, Bioproject Pharma) may be efficacious in severely affected narcoleptic patients with cataplexy. (practicalneurology.com)
  • The trial showed that pitolisant, which has previously shown to be active against EDS, was also able to significantly reduce cataplexy when given once-a-day for two months in severely affected patients. (practicalneurology.com)
  • Even if he preferred the term 'astasia' instead of 'cataplexy' the case described by him remained iconic for the full narcoleptic syndrome. (wikipedia.org)
  • Cataplexy may rapidly reoccur repeatedly, giving birth to "status cataplecticus" [4], and to the "limp man syndrome" as described by Stalh et al [7]. (scholarpedia.org)
  • Narcolepsy-cataplexy syndrome associated with DRB1*0806-DQB*0602 haplotype in a Caucasian patient. (semanticscholar.org)
  • These central nervous system disorders usually occur together in most dogs although narcolepsy can occur without cataplexy. (petplace.com)
  • but unlike fainting or seizure disorders, people who experience cataplexy are awake and aware of what's happening - though some may fall asleep after the episode ends. (everydayhealth.com)
  • Determining the mechanisms triggering loss of motoneuron function during REM sleep is important because breakdown in REM sleep motor control underlies sleep disorders such as REM sleep behavior disorder (RBD) and cataplexy/narcolepsy. (nih.gov)
  • A study by Anic-Labat et al reported that emotions arising from "hearing or telling a joke," "laughing," or "when angry," were most predictive of the loss of muscle function in clear-cut cataplexy [3]. (scholarpedia.org)
  • Cataplexy is the term given to sudden muscular weakness triggered by strong emotions such as laughter, anger and surprise. (narcolepsy.org.uk)
  • Cataplexy is a sudden and transient episode of loss of muscle tone, often triggered by emotions. (apneaboard.com)
  • An interesting fact about cataplexy is that it may be triggered by strong emotions, including laughter. (hubpages.com)
  • Most people with cataplexy have it because they have narcolepsy, a chronic neurological disorder whereby someone's sleep and wake cycles are disturbed. (everydayhealth.com)
  • Cataplexy is a brain disorder that causes a sudden and temporary loss of muscle tone and control. (everydayhealth.com)
  • The vast majority of people who experience cataplexy do so as a result of having type 1 narcolepsy, a chronic sleep and neurological disorder in which the brain has trouble properly controlling wake and sleep cycles. (everydayhealth.com)
  • While cataplexy is typically a sleep cycle disorder, catatonia is unrelated to sleep. (depressionalliance.org)
  • Narcolepsy with cataplexy is a sleep disorder caused by the loss of hypocretin-producing neurons in the hypothalamus. (cdc.gov)
  • Cataplexy is usually precipitated by emotion provoking laughter, anger, or joy. (bmj.com)
  • Cataplexy is triggered by stress or a strong emotion such as laughter, anger or surprise. (chop.edu)
  • Other conditions in which cataplexy can be seen include ischemic events, multiple sclerosis, head injury, paraneoplastic syndromes, and infections such as encephalitis. (wikipedia.org)
  • Narcoleptics often experience some form of cataplexy. (hubpages.com)
  • Abrupt loss of muscle tone, control and strength: this is known as cataplexy and it can even cause the body to collapse. (medic8.com)
  • What is your experience with cataplexy, do you have triggers? (sleep-disorders.net)
  • Again, I would suggest talking to a neurologist at a consult about his experience with cataplexy and if in fact you do have that along with hallucinations for this sence of feeling that someone is in fact sitting on you. (medhelp.org)
  • In this review, we will specifically focus on cataplexy and describe its clinical features, its association with the neurotransmitter hypocretin and the human leukocyte antigen DQB1*0602, as well as treatment options. (scholarpedia.org)
  • Thus, a lower hypoxic responsiveness in the narcolepsy-cataplexy group is a result of DQB1*0602 status rather than the clinical features of disease. (ersjournals.com)
  • The high frequency of HLA-DQB1*0602, low frequency of HLA-DQB1*0601 and low hypocretin levels in cataplexy-positive groups suggest that cataplexy-positive narcolepsy might be an etiologically different disease entity from the cataplexy-negative. (cdc.gov)
  • Type 1 narcolepsy (which was previously known as narcolepsy with cataplexy) involves a person having low levels of hypocretin or experiencing cataplexy and excessive daytime sleepiness. (mercola.com)
  • Type 2 narcolepsy (previously known as narcolepsy without cataplexy) experience excessive daytime sleepiness but typically do not have cataplexy. (mercola.com)
  • Type 2 narcolepsy is just abnormal daytime sleepiness without cataplexy. (redorbit.com)
  • Type 1 involves having excessive daytime sleepiness, cataplexy, and a low level of hypocretin. (medlineplus.gov)
  • Cataplexy involves an unexpected lack of muscle tone during wakefulness. (redorbit.com)
  • Cataplexy, an abnormal manifestation of REM sleep atonia, is currently treated with antidepressants. (nih.gov)
  • This review highlights recent work from my laboratory that examines how motoneuron function is lost during normal REM sleep and it also identifies potential biochemical mechanisms underlying abnormal motor control in both RBD and cataplexy. (nih.gov)
  • The underlying cause of cataplexy is unknown, but we do know that it is a neurological condition. (universityhealthnews.com)
  • Epworth sleepiness scale (ESS) and weekly cataplexy events were recorded. (kcl.ac.uk)
  • The National Niemann-Pick Disease Foundation notes that cataplexy itself is not a serious medical emergency, but because a cataplectic person may suddenly collapse (due to the rapid loss of muscle control), there "can be a anger if the person strikes his head while collapsing or lands awkwardly. (universityhealthnews.com)
  • A comparison of idiopathic hypersomnia and narcolepsy-cataplexy using self report measures and sleep diary data. (bmj.com)
  • Treatment with dexamethasone and chemotherapy resulted in rapid resolution of hypersomnia and cataplexy and gradual resolution of ataxia, followed by resection of the tumor. (pediatricneurologybriefs.com)
  • According to ICSD-III, narcolepsy is classified as distinct central nervous system hypersomnia in narcolepsy type 1 (NT1), formerly narcolepsy with cataplexy caused by a selective loss of hypothalamic neurons producing hypocretin, and narcolepsy type 2 (NT2), formerly narcolepsy without cataplexy and with normal hypocretin levels [ 1 ]. (springer.com)
  • The subject is lucid during this attack and it is important to recognize that consciousness is always maintained at the onset of cataplexy. (scholarpedia.org)
  • Narcolepsy-cataplexy consists of two underlying problems: (i) inability to maintain wakefulness, and (ii) intrusion of features of REM sleep into wakefulness or at sleep onset. (elsevier.com)
  • Cataplexy may also occur transiently or permanently due to lesions of the hypothalamus that were caused by surgery, especially in difficult tumor resections. (wikipedia.org)
  • The vast majority of cases of cataplexy occur because an individual has type 1 narcolepsy. (everydayhealth.com)
  • Narcolepsy can occur without cataplexy, and vice versa, although narcolepsy alone is difficult to recognize in dogs. (wiki-pet.com)
  • Selective serotonin reuptake inhibitors (SSRIs) are also useful in the treatment of cataplexy and their side effects are milder. (rxlist.com)
  • We therefore assessed the effects of sulpiride, a commonly used D2/D3 antagonist, on cataplexy and sleep in narcoleptic canines to explore the possible clinical application of D2/D3 antagonists for the treatment of human narcolepsy. (nih.gov)
  • These data confirm and expand previous reports on the good effects and tolerability of SO as a treatment for narcolepsy with cataplexy. (uzh.ch)
  • Pitolisant is a highly-selective histamine H3 receptor inverse agonist/antagonist that is indicated in adults for the treatment of narcolepsy with and without cataplexy. (practicalneurology.com)
  • The human model of hypocretin deficiency is narcolepsy with cataplexy 9 , 10 . (ersjournals.com)